|Ask||67.87 x 800|
|Day's Range||65.50 - 70.49|
|52 Week Range||31.38 - 80.11|
|PE Ratio (TTM)||-13.62|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.
We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.
Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.